RECRUITING

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Official Title

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Quick Facts

Study Start:2025-03-31
Study Completion:2028-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06523868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Active-duty or National Guard/Reserves military service for eight or more years
  2. * Age ≥ 45
  3. * Received care at a VA facility within past 5 years
  4. * Able to sign informed consent
  5. * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy
  1. * Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
  2. * Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
  3. * Individuals in the process of being evaluated for a clinical suspicion of cancer

Contacts and Locations

Study Contact

Elizabeth ODonnell, MD
CONTACT
857-215-2361
elizabeth_odonnell@dfci.harvard.edu

Principal Investigator

Elizabeth ODonnell, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Elizabeth ODonnell, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-31
Study Completion Date2028-09-30

Study Record Updates

Study Start Date2025-03-31
Study Completion Date2028-09-30

Terms related to this study

Keywords Provided by Researchers

  • Cancer Diagnosis

Additional Relevant MeSH Terms

  • Cancer Diagnosis